Skip to main content
Fig. 3 | Cancer & Metabolism

Fig. 3

From: An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells

Fig. 3

Changes in metabolites related to glycolysis, TCA cycle, and purine/pyrimidine metabolism of DFO-resistant HeLa cells. A Changes in glycolytic metabolites according to metabolome analysis (shown on the right). Schematic representation of the glycolytic pathway on the left. Cells were collected 2 days after DFO treatment and analyzed. The statistical differences between parent VEH vs parent DFO100, parent VEH vs resistant VEH, and resistant VEH vs resistant DFO100 are shown by *< 0.05 and **< 0.01 (ANOVA contrasts). B Changes in TCA cycle metabolites according to metabolome analysis. C Changes in purine and pyrimidine metabolism according to metabolome analysis

Back to article page

Cancer & Metabolism

ISSN: 2049-3002